| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 610 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | COAG Hemab Therapeutics Holdings, Inc. Common Stock | Ra Capital Management, L.P. | Director, 10% Owner | Buy | 2,840,429 | $18.39 | $52,222,945.65 | +9.9% | - | - | |
| May 5, 2026 | RLYB Rallybio Corporation | Adar1 Capital Management, LLC | 10% Owner | Buy | 155,905 | $13.97 | $2,178,668.31 | +7.8% | - | - | |
| May 5, 2026 | EWTX Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | Sell | 55,230 | $37.88 | $2,092,062.91 | -86.3% | - | - | |
| May 4, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | Sell | 8,256 | $23.31 | $192,415.26 | -3.1% | - | - | |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Dowden Nathan J | President &COO | Sell | 15,000 | $15.33 | $229,953.00 | -7.0% | - | - | |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sethuraman Natarajan | President, Research &Develop. | Sell | 25,907 | $15.39 | $398,809.77 | -10.7% | - | - | |
| May 4, 2026 | SPTX Seaport Therapeutics, Inc. Common Stock | Arch Venture Partners Xii, LLC | 10% Owner | Buy | 1,100,000 | $18.00 | $19,800,000.00 | +21.2% | - | - | |
| May 4, 2026 | SPRO Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | Sell | 25,240 | $2.51 | $63,352.40 | -2.5% | - | - | |
| May 4, 2026 | ACAD Acadia Pharmaceuticals Inc. | Schneyer Mark C. | EVP, Chief Financial Officer | Sell | 3,506 | $21.79 | $76,395.74 | -5.0% | - | - | |
| May 4, 2026 | ACAD Acadia Pharmaceuticals Inc. | Kihara James | Principal Accounting Officer | Sell | 1,332 | $21.79 | $29,024.28 | -4.4% | - | - | |
| May 4, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke | Director | Sell | 274,619 | $0.72 | $198,309.62 | -5.0% | - | - | |
| May 1, 2026 | BLTE Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $155.78 | $155,777.84 | -3.1% | - | - | |
| May 1, 2026 | IMVT Immunovant, Inc. | Susman Robert Graham | Director | Sell | 2,502 | $27.17 | $67,979.34 | -6.4% | - | - | |
| May 1, 2026 | CTNM Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | Sell | 4,170 | $13.12 | $54,694.20 | -1.4% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L | Chief Financial Officer | Sell | 12,500 | $71.37 | $892,125.00 | -11.3% | - | - | |
| May 1, 2026 | NRIX Nurix Therapeutics, Inc. | Ring Christine | Chief Legal Officer | Sell | 5,394 | $16.76 | $90,406.68 | -16.9% | - | - | |
| May 1, 2026 | PCVX Vaxcyte, Inc. | Wassil Jim | Chief Operating Officer | Sell | 2,250 | $56.83 | $127,869.75 | -1.4% | - | - | |
| May 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | Sell | 16,667 | $6.23 | $103,805.41 | -1.4% | - | - | |
| May 1, 2026 | TNGX Tango Therapeutics, Inc. | Crystal Adam | President, R&D | Sell | 27,000 | $21.23 | $573,097.33 | -10.4% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | Sell | 78,333 | $71.50 | $5,600,701.16 | -35.1% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $71.37 | $1,070,507.00 | -0.4% | - | - | |
| May 1, 2026 | REGN Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Director | Sell | 100 | $705.24 | $70,523.80 | - | - | - | |
| May 1, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Warmuth Markus | President &CEO | Sell | 5,467 | $18.92 | $103,446.57 | -0.9% | - | - | |
| May 1, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 10,000 | $4.16 | $41,592.00 | +0.3% | - | - | |
| May 1, 2026 | AVLN Avalyn Pharma Inc. Common Stock | Sr One Capital Management, LLC | 10% Owner | Buy | 555,555 | $18.00 | $9,999,990.00 | +20.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.